CodexisCDXS
Market Cap: 261M
About: Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
Employees: 174
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
50% more call options, than puts
Call options by funds: $30K | Put options by funds: $20K
3% more funds holding
Funds holding: 118 [Q4 2023] → 122 (+4) [Q1 2024]
3% more capital invested
Capital invested by funds: $182M [Q4 2023] → $187M (+$4.93M) [Q1 2024]
9.26% less ownership
Funds ownership: 85.62% [Q4 2023] → 76.36% (-9.26%) [Q1 2024]
15% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 48
Research analyst outlook
3 Wall Street Analysts provided 1 year price forecasts over the past 6 months
3 analyst ratings
Cantor Fitzgerald Kristen Kluska | 197%upside $11 | Overweight Initiated | 30 May 2024 |
Benchmark Robert Wasserman | 143%upside $9 | Buy Reiterated | 3 May 2024 |
Benchmark Robert Wasserman | 143%upside $9 | Buy Upgraded | 29 Feb 2024 |